ArvinasARVN +1.72%68 Days Inventory is 0.00 as of Mar. 2026. GuruFocus rates ARVN with a GF Score™ of 68/100 and a GF Value™ of $12.08 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 635 Biotechnology companies, Arvinas ranks worse than 157480.16% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Arvinas's Average Total Inventories for the
three
months ended in Mar. 2026 was $0.00 Mil. Arvinas's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.00 Mil.
The historical rank and industry rank for Arvinas's Days Inventory or its related term are showing as below:
ARVN's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.23 * Ranked among companies with meaningful Days Inventory only.
Arvinas's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Arvinas's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.00.
Arvinas (NAS:ARVN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Arvinas's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Arvinas's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Arvinas Days Inventory Related Terms
Arvinas Days Inventory Historical Data
* Premium members only.
The historical data trend for Arvinas's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARVN vs ZURA, KYTX, CBIO: Days Inventory Comparison
For the Biotechnology subindustry, Arvinas's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvinas Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arvinas's Days Inventory distribution charts can be found below:
* The bar in red indicates where Arvinas's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arvinas (ARVN) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Arvinas and its competitors. According to the industry distribution chart, Arvinas ranks #999999 out of 635 companies in the Biotechnology industry.
Is Arvinas' Days Inventory too high?
Arvinas' current Days Inventory is 0.00. Based on the distribution chart, Arvinas ranks #999999 out of 635 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arvinas has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arvinas' Days Inventory compare to ZURA and KYTX?
According to the Biotechnology industry distribution chart, Arvinas ranks #999999 out of 635 companies for Days Inventory. This places Arvinas in the lower half of its industry. The industry median Days Inventory is 183.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Arvinas and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arvinas's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvinas stock overvalued right now?
Based on GuruFocus' analysis, Arvinas (ARVN) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.08, compared to a current price of $8.59 — trading 28.9% below its estimated fair value. The current Days Inventory is 0.00. Arvinas' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Arvinas (ARVN), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvinas (ARVN) Overvalued in 2026?
Based on GuruFocus' analysis, Arvinas stock appears to be undervalued.
The current stock price of $8.59 is trading 28.9% below its estimated GF Value™ of $12.08.
GuruFocus considers Arvinas to be Modestly Undervalued.
Key valuation signals for ARVN:
Days Inventory: 0.00
GF Value™: $12.08 vs. price of $8.59 (28.9% below fair value)
No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
68GF Score
Get the complete analysis for ARVN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARVN has been successfully added to your 
